Don't see this as a bad thing personally. Glad to see they are...

Don't see this as a bad thing personally. Glad to see they are not just resting on their laurels with the first generic approval but actively pursuing the progression of the rest of their portfolio, (and oral application of fondaparinux which I think would be a fantastic development!).

And glad that it's a rights issue and not an SPP record-dated Dec 3, so people can't just buy $500 parcels and take advantage of the significant % discount of the 53c shares.
FDA approval might still come through before this rights issue and you'll be thanking them for the chance to get a few more shares at that price... I'm happy to see them trying to add shareholder value without substantial dilution.